Semaglutide Week 16: What to Expect, Weight Loss & Side Effects
Semaglutide week 16 completes four months of treatment. Evaluate your progress at 1.0 mg, discuss next steps with your provider, and understand when moving to 1.7 mg makes clinical sense.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This article covers week 16 of semaglutide treatment at the 1.0 mg dose, including expected weight loss, side effects, diet recommendations, and when to contact your healthcare provider.
Quick links: Semaglutide treatment, full results timeline, and week-by-week guide.
More on Semaglutide Timeline
Semaglutide Week 15
What to expect during week 15 of semaglutide treatment.
Semaglutide Week 17
What to expect during week 17 of semaglutide treatment.
Semaglutide Weight Loss Results
Complete overview of semaglutide weight loss results by timeframe.
Week-by-Week Semaglutide Guide
Full timeline of what to expect on semaglutide treatment.
Week 16 on Semaglutide: The 1.0 mg Therapeutic Dose
Week 16 of semaglutide treatment has you continuing the 1.0 mg therapeutic dose, where the medication's weight loss effects are fully engaged. This is the phase where patients in the STEP clinical trials began seeing the most significant and visible results. The 1.0 mg dose represents a four-fold increase from the starting dose and activates GLP-1 receptors at a level that produces meaningful changes in appetite, metabolism, and body composition.
As you complete four months of treatment, you are at a decision point. Patients who have achieved satisfactory results at 1.0 mg may continue at this dose. Those who need additional weight loss or have experienced a plateau may benefit from increasing to 1.7 mg. This decision should be made in collaboration with your healthcare provider based on your individual response and goals.
Your cumulative weight loss at week 16 is likely in the range of 23 to 32 pounds. For the full picture of how results develop across the treatment timeline, see our detailed GLP-1 complete guide. Managing your progress alongside proper nutrition is essential at this stage, and our semaglutide dose escalation guide can help optimize your outcomes. Consider comparing your options with semaglutide injection technique if you are evaluating providers.
Managing Side Effects at Week 16 on 1.0 mg
By week 16 on the 1.0 mg therapeutic dose, your body has had significant time to adapt to semaglutide. Most patients experience substantially fewer side effects than during the earlier dose phases. The side effects that remain tend to be mild and predictable.
GI side effects are generally well-controlled and primarily triggered by dietary choices rather than the medication itself. Eating slowly, choosing lean proteins and vegetables, and avoiding large fatty meals minimizes symptoms
Constipation may be the most persistent side effect at this point. A consistent fiber supplementation routine, adequate hydration, and regular physical activity are the most effective management strategies
Most patients at this dose level report that the appetite suppression feels natural rather than forced, indicating excellent medication tolerance
Hair thinning or increased shedding, known as telogen effluvium, can occur with significant weight loss and may become noticeable around this timeframe. This is related to caloric deficit and weight loss rather than the medication itself
Heartburn or acid reflux is reported by approximately 10 to 15 percent of patients at the 1.0 mg dose. Eating smaller meals and avoiding lying down immediately after eating helps manage this symptom
For a full guide on side effects at every dose level, see semaglutide side effects. If your side effects have not improved by this point or have worsened, discuss dose adjustment options with your provider.
Weight Loss Progress at Week 16
At week 16 on the 1.0 mg dose, typical cumulative weight loss ranges from 23 to 32 pounds, representing approximately 12 to 16 percent of starting body weight. This is the phase where results become visually apparent and measurable in ways beyond just the scale, including improved clothing fit, better lab values, and enhanced physical capacity.
Week 16 Weight Loss Benchmark
Expected cumulative loss: 23 to 32 pounds (12 to 16 percent of starting body weight). Current dose: 1.0 mg. Individual results vary based on adherence, diet, exercise, and metabolic factors. These figures are based on clinical trial averages and real-world patient data.
As you approach or exceed 15 percent body weight reduction, your body is making significant metabolic adaptations. Your resting metabolic rate may decrease as you weigh less, which is a normal physiological response. This is why maintaining muscle mass through resistance training and adequate protein intake is critical at this stage.
For the complete picture of expected results at every timeframe, see our comprehensive exercise on GLP-1 medications. Patients looking for the most affordable access to semaglutide can also explore cheapest GLP-1 injections in 2026.
Advanced Nutrition at Week 16
By week 16 on the 1.0 mg dose, your nutritional approach should be transitioning from a weight loss diet to a sustainable long-term eating pattern. The habits you establish now will determine whether you maintain your results in the months and years ahead.
Maintain high protein intake of 0.8 to 1.0 grams per pound of lean body mass: This remains the single most important dietary factor for preserving muscle mass and maintaining metabolic rate during continued weight loss
Practice intuitive eating alongside medication: Begin tuning into natural hunger and fullness signals. While semaglutide significantly reduces appetite, learning to eat intuitively prepares you for potential future dose reduction
Focus on whole food variety: Rotate through different protein sources, vegetables, fruits, and whole grains weekly to ensure broad micronutrient coverage and prevent diet fatigue
Manage portion sizes without strict calorie counting: At this stage, your reduced appetite naturally limits caloric intake. Focus on food quality rather than obsessive tracking, which can become counterproductive long-term
Consider working with a registered dietitian: A professional can help optimize your nutrition for your specific body composition goals, activity level, and any nutritional deficiencies identified through bloodwork
For detailed meal planning guidance tailored to your treatment phase, see our guide on diet tips while on semaglutide. Pairing proper nutrition with exercise on GLP-1 medications maximizes your results during this critical phase.
Breaking Through Plateaus at Week 16
By week 16, some patients encounter their first significant weight loss plateau. A plateau is defined as no weight change for three or more consecutive weeks despite maintaining your treatment regimen. While frustrating, plateaus are a normal part of the weight loss process and do not indicate treatment failure.
Reassess your caloric intake: As you lose weight, your body requires fewer calories. What was a deficit at your starting weight may be maintenance at your current weight. Consider recalculating your needs
Increase physical activity intensity: If your body has adapted to your current exercise routine, increasing intensity or duration can restart progress. Adding interval training or increasing resistance training load are effective approaches
Evaluate hydration and sodium intake: Water retention can mask ongoing fat loss. Ensure adequate hydration and moderate sodium intake to minimize fluid fluctuations
Discuss dose optimization with your provider: If you have not yet reached the next dose level, a dose increase may be appropriate to overcome the plateau
Focus on body composition rather than scale weight: You may be simultaneously losing fat and gaining muscle, especially if you have been strength training. Measurements and clothing fit are often better indicators than the scale alone
For evidence-based plateau-breaking strategies, review our GLP-1 complete guide and explore how exercise on GLP-1 medications can complement your treatment.
Frequently Asked Questions
Is 23 to 32 pounds of weight loss normal at week 16?
Yes, losing 23 to 32 pounds by week 16 on the 1.0 mg dose falls within the expected clinical range. The STEP clinical trials showed that patients on semaglutide 2.4 mg achieved an average of 15 to 17 percent body weight reduction over 68 weeks, with the majority of loss occurring in the first 6 months. At week 16, you are in the phase where results accelerate significantly. If your weight loss is below this range, discuss dose optimization with your provider. If it exceeds this range, ensure you are maintaining adequate nutrition and not losing weight too rapidly.
Are side effects still common at week 16?
By week 16, most patients have significantly adapted to semaglutide and side effects are substantially reduced compared to the starting weeks. The most common remaining effects are mild appetite suppression (which is the desired therapeutic effect) and occasional GI symptoms that typically occur only after eating large meals or particularly fatty foods. Less than 10 percent of patients who tolerate the medication through the first 8 weeks discontinue due to side effects at later stages. If you are experiencing new or worsening symptoms at this point in treatment, it warrants a conversation with your provider as it may indicate a need for dose adjustment.
Should I rotate injection sites at week 16?
Yes, injection site rotation remains important throughout your entire course of semaglutide treatment, including at week 16. Consistently injecting in the same spot can cause lipodystrophy, which affects how the medication is absorbed and can create cosmetically undesirable lumps or indentations under the skin. Rotate between the abdomen (left and right sides), thighs, and upper arms. Some patients develop a preferred site, which is fine as long as you use different spots within that general area each week. Keep at least one inch between consecutive injection points in the same body region.
How should my diet change at week 16 on semaglutide?
By week 16, your dietary approach should be well-established, but there are refinements worth making at the 1.0 mg dose. Protein remains paramount, aiming for 0.7 to 1.0 grams per pound of lean body mass to prevent muscle loss, which becomes increasingly important as total weight loss accumulates. Many patients find their food preferences have shifted naturally, with decreased interest in highly processed and sugary foods. This is a good time to introduce more variety in your vegetable intake, experiment with lean protein sources, and ensure you are getting adequate fiber from whole grains, legumes, and vegetables. Stay well-hydrated with at least 64 ounces of water daily, and consider a daily multivitamin to cover any potential micronutrient gaps from reduced caloric intake.
What exercise routine is best at week 16?
By week 16, most patients are well-adapted to semaglutide and can engage in more structured exercise programs. A combination of cardiovascular exercise (150 minutes per week of moderate intensity) and resistance training (two to three sessions per week) is ideal. Resistance training is especially important at this stage because as you lose significant weight, you want to preserve as much lean muscle mass as possible. Muscle mass drives your resting metabolic rate, so protecting it helps prevent the metabolic slowdown that can occur with weight loss. If you were previously limited by joint pain or mobility issues, you may find that your reduced body weight now allows activities that were uncomfortable before. Progressive overload in your strength training and gradually increasing your cardio duration or intensity will keep your body adapting and support continued weight loss.
When should I contact my doctor during week 16 of semaglutide?
Contact your healthcare provider promptly if you experience any of the following during week 16: severe or persistent nausea or vomiting that prevents you from keeping food or liquids down for more than 24 hours, severe abdominal pain that does not resolve with over-the-counter remedies, signs of pancreatitis including intense upper abdominal pain radiating to the back, symptoms of gallbladder problems such as sharp pain under the right rib cage after eating, signs of hypoglycemia including shakiness and confusion and sweating especially if you take other diabetes medications, any allergic reaction symptoms such as swelling of the face or throat or difficulty breathing, or changes in vision. Also contact your provider if you are losing weight too rapidly, defined as more than four pounds per week consistently, or if you have gained weight unexpectedly, which may indicate the dose needs adjustment.
How long will I need to take semaglutide?
Semaglutide for weight management is generally considered a long-term treatment. Clinical trials that demonstrated the 15 to 17 percent body weight reduction used 68-week treatment protocols, and follow-up studies show that discontinuing the medication often leads to partial weight regain. Most healthcare providers recommend planning for at least 12 to 18 months of treatment to achieve and stabilize your weight loss. After that, you and your provider will discuss whether to continue at the current dose, reduce to a maintenance dose, or transition to lifestyle-only management. The best approach is to focus on building sustainable diet and exercise habits now while the medication supports your efforts, so that if you do eventually reduce or stop the medication, you have a strong foundation of healthy behaviors in place.
Sources & References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM 2021 (STEP 1 trial).
- Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 2). Lancet 2021.
- Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as adjunct to intensive behavioral therapy (STEP 3).
- Wegovy (semaglutide) prescribing information. FDA.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4).
- NIDDK: Prescription medications to treat overweight and obesity.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity (SELECT trial). NEJM 2023.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, adjusting, or discontinuing any medication. Individual results vary and the weight loss figures cited represent clinical trial averages, not guaranteed outcomes. Semaglutide requires a prescription and should only be used under medical supervision.